In March 2025, Sanofi announced that its Tolebrutinib regulatory submission for multiple sclerosis was accepted for priority review in the US on March 25, and that a Chlamydia vaccine candidate received fast track designation from the FDA on March 26. This is a significant event for the company with a positive sentiment.